Interdisciplinary cancer research, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
MedComm, Journal Year: 2024, Volume and Issue: 5(6)
Published: May 23, 2024
CD44, a nonkinase single span transmembrane glycoprotein, is major cell surface receptor for many other extracellular matrix components as well classic markers of cancer stem cells and immune cells. Through alternative splicing
Language: Английский
Citations
9
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(21), P. 15812 - 15812
Published: Oct. 31, 2023
Hyaluronic acid (HA) receptor CD44 is widely used for identifying cancer stem cells and its activation promotes stemness. Recent evidence shows that overexpression of associated with poor prognosis in most human cancers mediates therapy resistance. For these reasons, recent years, has become a treatment target precision oncology, often via HA-conjugated antineoplastic drugs. Importantly, HA molecules different sizes have dual effect and, therefore, may enhance or attenuate the CD44-mediated signaling pathways, as they compete endogenous binding to receptors. The magnitude effects could be crucial progression, well driving inflammatory response tumor microenvironment. increasingly common use drugs HA-based compounds adjuvants treatment, adds further complexity understanding net hyaluronan-CD44 cancers. In this review, I focus on significance malignancy discuss dichotomous function hyaluronan/CD44 axis progression.
Language: Английский
Citations
20
Molecular and Cellular Probes, Journal Year: 2025, Volume and Issue: unknown, P. 102028 - 102028
Published: March 1, 2025
Language: Английский
Citations
0
Cell Death and Disease, Journal Year: 2025, Volume and Issue: 16(1)
Published: April 16, 2025
Language: Английский
Citations
0
Molecules, Journal Year: 2024, Volume and Issue: 29(11), P. 2623 - 2623
Published: June 3, 2024
Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, promotes the cytotoxicity of genotoxic anticancer drug cisplatin, yet underlying mechanism remains poorly understood. Herein, we revealed that TSA at low concentration (1 μM) promoted cisplatin-induced activation caspase-3/6, which, in turn, increased level cleaved PARP1 and degraded lamin A&C, leading to more apoptosis G2/M phase arrest A549 cancer cells. Both ICP-MS ToF-SIMS measurements demonstrated significant increase DNA-bound platinum cells presence TSA, which was attributable TSA-induced accessibility genomic DNA cisplatin attacking. The global quantitative proteomics results further showed activated INF signaling upregulate STAT1 SAMHD1 sensitivity downregulated ICAM1 CD44 reduce cell migration, synergistically promoting cytotoxicity. Furthermore, TFAM SLC3A2 enhance ferroptosis, also contributing promotion Importantly, our posttranslational modification data indicated acetylation H4K8 played dominant role These findings provide novel insights into better understanding principle combining chemotherapy drugs HDAC inhibitors for treatment cancers.
Language: Английский
Citations
3
Cancer Gene Therapy, Journal Year: 2025, Volume and Issue: unknown
Published: March 15, 2025
Abstract We have recently demonstrated that genetic inactivation of EWSR1 : FLI1 by CRISPR/Cas9, successfully blocks cell proliferation in a model Ewing sarcoma. However, CRISPR/Cas9-mediated gene editing can exhibit off-target effects, and thus, precise regulation Cas9 expression target cells is essential to develop gene-editing strategies inactivate sarcoma cells. In this study, we demonstrate be specifically expressed when located downstream promoter consisting GGAA repeats consensus TATA box (GGAAprom). Under these conditions, selectively express oncoproteins, but not expressing wild-type FLI1. Consequently, infected with GGAAprom>Cas9 specific gRNA designed FLI1, showed successful the subsequent blockade proliferation. Notably, efficiently delivered via adenoviral vectors both vitro vivo, highlighting potential approach for treatment. Our results CRISPR/Cas9 machinery safe driven under GGAAprom, paving way development cancer therapies based on selective genes therapeutic potential.
Language: Английский
Citations
0
bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 20, 2024
Abstract Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric diagnoses. Patients who present with metastatic disease at time diagnosis have a dismal prognosis, compared to >70% 5-year survival those localized disease. Here, we utilized single cell RNA-sequencing characterize transcriptional landscape primary tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution within patients prior treatment. Primary samples demonstrate heterogenous several conserved gene expression programs, including composed genes related proliferation EWS targets. Single immunofluorescence circulating cells TSPAN8 as novel therapeutic target.
Language: Английский
Citations
2
Advances in Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(06), P. 1490 - 1494
Published: Jan. 1, 2024
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6609 - 6609
Published: June 15, 2024
Due to the rarity and heterogeneity of sarcoma, investigation into molecular targets new treatments has been particularly challenging [...].
Language: Английский
Citations
0
Interdisciplinary cancer research, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Citations
0